Omnitrope approval raises concerns in biotech industry

The FDA's recent approval of a generic version of Pfizer's biotech drug Genotropin has raised concerns in the industry about a possible change in approval of copies of biotech drugs. The biotech industry has long argued its products are too complex to be copied safely, and Congress and the FDA hesitated allowing copies; but the generics industry is pushing for a more flexible policy.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA